Is Par Drugs and Chemicals the Best Stock in Its Sector? A Look at the Numbers

Is Par Drugs and Chemicals the best stock in its sector? The stock trades on the NSE at Rs 125 as of 05 October 2026, within its 52-week range of Rs 78.05 to Rs 180.00. Par Drugs and Chemicals Ltd, based in Vadodara, makes magnesium-based active pharmaceutical ingredients and antacid raw materials at its Bhavnagar plant.

Par Drugs and Chemicals sits in the Healthcare sector, and its 11.71% ROE and 10.52x P/E give a starting point for judging where it stands against comparable listed names. The rest of this article compares those numbers against verified peers and the sector's Industry P/E benchmark.

Also read – Is Abbott India the Best Stock in Its Sector? A Look at the Numbers

Click Here – Get Free Investment Predictions

About Par Drugs and Chemicals

Par Drugs and Chemicals Ltd, based in Vadodara, makes magnesium-based active pharmaceutical ingredients and antacid raw materials at its Bhavnagar plant. The stock rose about 1 percent during this session and is trading in the lower half of its 52-week range, about 31 percent below its high. At a market capitalisation of Rs 153 Cr, it is tracked as part of the Healthcare sector on Univest.

Is Par Drugs and Chemicals the Best Stock in Its Sector?

Par Drugs and Chemicals makes its case as the best stock in its sector primarily on valuation relative to its Industry P/E, combining a 11.71% ROE with a 10.52x P/E against the sector's 50.45x Industry P/E. Par Drugs and Chemicals' 10.52x P/E is far below the 50.45x Industry P/E despite an 11.71% ROE, making it look inexpensive relative to its own quality, though it is a small-cap with thin trading.

Metric	Par Drugs and Chemicals
CMP (NSE)	Rs 125.00
52-Week High / Low	Rs 180.00 / Rs 78.05
Market Cap	Rs 153 Cr
P/E (TTM) vs Industry P/E	10.52x vs 50.45x
P/B	1.36
ROE	11.71%
EPS (TTM)	Rs 11.78
Dividend Yield	0.00%
Debt to Equity	0.00

Compare Par Drugs and Chemicals Against Other Healthcare Sector Stocks

How Par Drugs and Chemicals Compares Against Its Healthcare Sector Peers

The table below sets Par Drugs and Chemicals against 2 other Healthcare sector names, using the same live data source for every company. A peer average row is included for P/E, ROE and debt to equity, calculated across the 2 peer companies.

Company	Market Cap (Rs Cr)	P/E	ROE	Debt to Equity
Par Drugs and Chemicals	153	10.52	11.71%	0.00
Lincoln Pharmaceuticals	1,172	12.15	11.60%	0.01
Medico Remedies	179	13.00	17.38%	0.25
Peer average (2 companies)	-	12.57	14.49%	0.13

Against this peer set, Par Drugs and Chemicals's 11.71% ROE is below the 14.49% peer average, and its P/E of 10.52x runs below the peer average of 12.57x. Par Drugs and Chemicals' 10.52x P/E is far below the 50.45x Industry P/E despite an 11.71% ROE, making it look inexpensive relative to its own quality, though it is a small-cap with thin trading.

What Makes Par Drugs and Chemicals Worth Watching in Healthcare

• Well below Industry P/E: A 10.52x P/E against a 50.45x Industry P/E is a wide discount for a business with an 11.71% ROE.
• Debt free balance sheet: A debt to equity ratio of 0.00 gives Par Drugs and Chemicals complete flexibility to fund operations internally.
• Antacid ingredients niche: Being a large producer of magnesium hydroxide and sucralfate gives Par Drugs and Chemicals a specialised position in antacid raw materials.

Par Drugs and Chemicals Valuation: Is It Justified?

Par Drugs and Chemicals' 10.52x P/E is far below the 50.45x Industry P/E despite an 11.71% ROE, making it look inexpensive relative to its own quality, though it is a small-cap with thin trading. As with any single stock, investors should weigh this against their own valuation discipline and risk appetite rather than the sector label alone.

Also read – Is Oricon Enterprises the Best Stock in Its Sector? A Look at the Numbers

Download the Univest iOS App or Univest Android App to track Par Drugs and Chemicals and other Healthcare sector stocks.

How to Track Par Drugs and Chemicals Before You Invest

Before deciding whether Par Drugs and Chemicals deserves its label as the best stock in its sector for your own portfolio, compare it directly against Healthcare sector peers using the steps below.

1. Open the Univest Screener and search for Par Drugs and Chemicals to view live price, valuation ratios, and peer comparisons within the Healthcare sector.
2. Compare its P/E, P/B, and ROE against other Healthcare sector stocks before deciding if the current valuation fits your strategy.
3. Set a price alert around key support and resistance zones using the Univest app so you are notified of meaningful moves.
4. Open a broking account on Univest if you decide to add the stock, and size the position based on your own risk appetite and portfolio allocation.

Conclusion

Par Drugs and Chemicals earns a place in the best stock in its sector conversation on the strength of a 11.71% ROE and a P/E of 10.52x against a 50.45x Industry P/E, with named peer comparisons in this article backing up that picture. As with any individual stock decision, this analysis is educational and investors should do their own research or consult a SEBI-registered advisor before investing.

Is Par Drugs and Chemicals the best stock in its sector?

Ans. Par Drugs and Chemicals has a 11.71% ROE and trades at 10.52x P/E against a 50.45x Industry P/E, and compares below the peer average ROE of 14.49% in this article's named comparison, so the answer depends on what an investor is prioritising.

What is the current share price of Par Drugs and Chemicals?

Ans. Par Drugs and Chemicals was trading at Rs 125.00 on the NSE as of 05 October 2026, within its 52-week range of Rs 78.05 to Rs 180.00.

What sector does Par Drugs and Chemicals belong to?

Ans. Par Drugs and Chemicals is classified under the Healthcare sector on Univest.

How does Par Drugs and Chemicals compare to its sector peers on P/E?

Ans. Par Drugs and Chemicals's P/E of 10.52x is below the 12.57x average of the 2 named peers compared in this article.

What is Par Drugs and Chemicals's return on equity?

Ans. Par Drugs and Chemicals reported a return on equity of 11.71%, which is below the 14.49% average of its named peers in this comparison.

Should I invest in Par Drugs and Chemicals based on its sector position?

Ans. Par Drugs and Chemicals's sector position and metrics make it worth researching further, but any investment decision should factor in your own risk appetite, its valuation relative to peers, and independent research or advice from a SEBI-registered advisor.

{"@context": "https://schema.org", "@type": "FAQPage", "mainEntity": [{"@type": "Question", "name": "Is Par Drugs and Chemicals the best stock in its sector?", "acceptedAnswer": {"@type": "Answer", "text": "Par Drugs and Chemicals has a 11.71% ROE and trades at 10.52x P/E against a 50.45x Industry P/E, and compares below the peer average ROE of 14.49% in this article's named comparison, so the answer depends on what an investor is prioritising."}}, {"@type": "Question", "name": "What is the current share price of Par Drugs and Chemicals?", "acceptedAnswer": {"@type": "Answer", "text": "Par Drugs and Chemicals was trading at Rs 125.00 on the NSE as of 05 October 2026, within its 52-week range of Rs 78.05 to Rs 180.00."}}, {"@type": "Question", "name": "What sector does Par Drugs and Chemicals belong to?", "acceptedAnswer": {"@type": "Answer", "text": "Par Drugs and Chemicals is classified under the Healthcare sector on Univest."}}, {"@type": "Question", "name": "How does Par Drugs and Chemicals compare to its sector peers on P/E?", "acceptedAnswer": {"@type": "Answer", "text": "Par Drugs and Chemicals's P/E of 10.52x is below the 12.57x average of the 2 named peers compared in this article."}}, {"@type": "Question", "name": "What is Par Drugs and Chemicals's return on equity?", "acceptedAnswer": {"@type": "Answer", "text": "Par Drugs and Chemicals reported a return on equity of 11.71%, which is below the 14.49% average of its named peers in this comparison."}}, {"@type": "Question", "name": "Should I invest in Par Drugs and Chemicals based on its sector position?", "acceptedAnswer": {"@type": "Answer", "text": "Par Drugs and Chemicals's sector position and metrics make it worth researching further, but any investment decision should factor in your own risk appetite, its valuation relative to peers, and independent research or advice from a SEBI-registered advisor."}}]}